# FiH Safety and Feasibility Study Assessing Intra-articular Administration of aeGF in Patients With Knee Osteoarthritis

> **NCT06690710** · PHASE1 · RECRUITING · sponsor: **Scarcell Therapeutics S.A.S.** · enrollment: 15 (estimated)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **BIOLOGICAL:** allogeneic engineered Gingival Fibroblasts (aeGF)

## Key facts

- **NCT ID:** NCT06690710
- **Lead sponsor:** Scarcell Therapeutics S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2027-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690710, "FiH Safety and Feasibility Study Assessing Intra-articular Administration of aeGF in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06690710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*